Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 378

1.

Tunable Plasma-Based Energy Dechirper.

D'Arcy R, Wesch S, Aschikhin A, Bohlen S, Behrens C, Garland MJ, Goldberg L, Gonzalez P, Knetsch A, Libov V, de la Ossa AM, Meisel M, Mehrling TJ, Niknejadi P, Poder K, Röckemann JH, Schaper L, Schmidt B, Schröder S, Palmer C, Schwinkendorf JP, Sheeran B, Streeter MJV, Tauscher G, Wacker V, Osterhoff J.

Phys Rev Lett. 2019 Jan 25;122(3):034801. doi: 10.1103/PhysRevLett.122.034801.

PMID:
30735413
2.

Transport of Anthocyanins and other Flavonoids by the Arabidopsis ATP-Binding Cassette Transporter AtABCC2.

Behrens CE, Smith KE, Iancu CV, Choe JY, Dean JV.

Sci Rep. 2019 Jan 24;9(1):437. doi: 10.1038/s41598-018-37504-8.

3.

Oxime Coupling of Active Site Inhibited Factor Seven with a Nonvolatile, Water-Soluble Fluorine-18 Labeled Aldehyde.

Jeppesen TE, Kristensen LK, Nielsen CH, Petersen LC, Kristensen JB, Behrens C, Madsen J, Kjaer A.

Bioconjug Chem. 2019 Feb 6. doi: 10.1021/acs.bioconjchem.8b00900. [Epub ahead of print]

PMID:
30676028
4.

Inhibitor of Differentiation-1 Sustains Mutant KRAS-Driven Progression, Maintenance, and Metastasis of Lung Adenocarcinoma via Regulation of a FOSL1 Network.

Román M, López I, Guruceaga E, Baraibar I, Ecay M, Collantes M, Nadal E, Vallejo A, Cadenas S, Miguel ME, Jang JH, Martin-Uriz PS, Castro-Labrador L, Vilas-Zornoza A, Lara-Astiaso D, Ponz-Sarvise M, Rolfo C, Santos ES, Raez LE, Taverna S, Behrens C, Weder W, Wistuba II, Vicent S, Gil-Bazo I.

Cancer Res. 2019 Feb 1;79(3):625-638. doi: 10.1158/0008-5472.CAN-18-1479. Epub 2018 Dec 18.

PMID:
30563891
5.

Acute Effects of Exercise Intensity on Insulin Sensitivity under Energy Balance.

Fisher G, Gower BA, Ovalle F, Behrens CE, Hunter GR.

Med Sci Sports Exerc. 2018 Dec 13. doi: 10.1249/MSS.0000000000001872. [Epub ahead of print]

PMID:
30550514
6.

5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging.

Martínez-Terroba E, Behrens C, Agorreta J, Monsó E, Millares L, Felip E, Rosell R, Ramirez JL, Remirez A, Torre W, Gil-Bazo I, Idoate MA, de-Torres JP, Pio R, Wistuba II, Pajares MJ, Montuenga LM.

Thorax. 2018 Nov 24. pii: thoraxjnl-2018-212194. doi: 10.1136/thoraxjnl-2018-212194. [Epub ahead of print]

PMID:
30472670
7.

Sex specific function of epithelial STAT3 signaling in pathogenesis of K-ras mutant lung cancer.

Caetano MS, Hassane M, Van HT, Bugarin E, Cumpian AM, McDowell CL, Cavazos CG, Zhang H, Deng S, Diao L, Wang J, Evans SE, Behrens C, Wistuba II, Fuqua SAW, Lin H, Stabile LP, Watowich SS, Kadara H, Moghaddam SJ.

Nat Commun. 2018 Nov 2;9(1):4589. doi: 10.1038/s41467-018-07042-y.

8.

Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of RICTOR/KRAS-altered non-small cell lung cancer.

Ruder D, Papadimitrakopoulou V, Shien K, Behrens C, Kalhor N, Chen H, Shen L, Lee JJ, Hong WK, Tang X, Girard L, Minna JD, Diao L, Wang J, Mino B, Villalobos P, Rodriguez-Canales J, Hanson NE, Sun J, Miller V, Greenbowe J, Frampton G, Herbst RS, Baladandayuthapani V, Wistuba II, Izzo JG.

Oncotarget. 2018 Sep 21;9(74):33995-34008. doi: 10.18632/oncotarget.26129. eCollection 2018 Sep 21.

9.

Validation of the 12-gene Predictive Signature for Adjuvant Chemotherapy Response in Lung Cancer.

Xie Y, Lu W, Wang S, Tang X, Tang H, Zhou Y, Moran C, Behrens C, Roth JA, Zhou Q, Johnson DH, Swisher SG, Heymach JV, Papadimitrakopoulou VA, Xiao G, Minna JD, Wistuba II.

Clin Cancer Res. 2019 Jan 1;25(1):150-157. doi: 10.1158/1078-0432.CCR-17-2543. Epub 2018 Oct 4.

PMID:
30287547
10.

Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer.

Su Y, Liu Y, Behrens CR, Bidlingmaier S, Lee NK, Aggarwal R, Sherbenou DW, Burlingame AL, Hann BC, Simko JP, Premasekharan G, Paris PL, Shuman MA, Seo Y, Small EJ, Liu B.

JCI Insight. 2018 Sep 6;3(17). pii: 121497. doi: 10.1172/jci.insight.121497. [Epub ahead of print]

11.

The oncogenic RNA-binding protein SRSF1 regulates LIG1 in non-small cell lung cancer.

Martínez-Terroba E, Ezponda T, Bértolo C, Sainz C, Remírez A, Agorreta J, Garmendia I, Behrens C, Pio R, Wistuba II, Montuenga LM, Pajares MJ.

Lab Invest. 2018 Dec;98(12):1562-1574. doi: 10.1038/s41374-018-0128-2. Epub 2018 Sep 4.

PMID:
30181552
12.

Long-Acting Human Growth Hormone Analogue by Noncovalent Albumin Binding.

Ramírez-Andersen HS, Behrens C, Buchardt J, Fels JJ, Folkesson CG, Jianhe C, Nørskov-Lauritsen L, Nielsen PF, Reslow M, Rischel C, Su J, Thygesen P, Wiberg C, Zhao X, Wenjuan X, Johansen NL.

Bioconjug Chem. 2018 Sep 19;29(9):3129-3143. doi: 10.1021/acs.bioconjchem.8b00463. Epub 2018 Aug 31.

PMID:
30168709
13.

The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network.

Tan X, Banerjee P, Liu X, Yu J, Gibbons DL, Wu P, Scott KL, Diao L, Zheng X, Wang J, Jalali A, Suraokar M, Fujimoto J, Behrens C, Liu X, Liu CG, Creighton CJ, Wistuba II, Kurie JM.

J Clin Invest. 2018 Jul 2;128(7):3198. doi: 10.1172/JCI122740. Epub 2018 Jul 2. No abstract available.

14.

Rare Variants in Known Susceptibility Loci and Their Contribution to Risk of Lung Cancer.

Liu Y, Lusk CM, Cho MH, Silverman EK, Qiao D, Zhang R, Scheurer ME, Kheradmand F, Wheeler DA, Tsavachidis S, Armstrong G, Zhu D, Wistuba II, Chow CB, Behrens C, Pikielny CW, Neslund-Dudas C, Pinney SM, Anderson M, Kupert E, Bailey-Wilson J, Gaba C, Mandal D, You M, de Andrade M, Yang P, Field JK, Liloglou T, Davies M, Lissowska J, Swiatkowska B, Zaridze D, Mukeriya A, Janout V, Holcatova I, Mates D, Milosavljevic S, Scelo G, Brennan P, McKay J, Liu G, Hung RJ, Christiani DC, Schwartz AG, Amos CI, Spitz MR.

J Thorac Oncol. 2018 Oct;13(10):1483-1495. doi: 10.1016/j.jtho.2018.06.016. Epub 2018 Jul 4.

PMID:
29981437
15.

BadGluc, a β-glucosidase from Bjerkandera adusta with anthocyanase properties.

Behrens CJ, Krahe NK, Linke D, Berger RG.

Bioprocess Biosyst Eng. 2018 Sep;41(9):1391-1401. doi: 10.1007/s00449-018-1966-4. Epub 2018 Jun 12.

PMID:
29948211
16.

Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches.

Parra ER, Villalobos P, Behrens C, Jiang M, Pataer A, Swisher SG, William WN Jr, Zhang J, Lee J, Cascone T, Heymach JV, Forget MA, Haymaker C, Bernatchez C, Kalhor N, Weissferdt A, Moran C, Zhang J, Vaporciyan A, Gibbons DL, Sepesi B, Wistuba II.

J Immunother Cancer. 2018 Jun 6;6(1):48. doi: 10.1186/s40425-018-0368-0.

17.

Homodimer Architecture of QTRT2, the Noncatalytic Subunit of the Eukaryotic tRNA-Guanine Transglycosylase.

Behrens C, Biela I, Petiot-Bécard S, Botzanowski T, Cianférani S, Sager CP, Klebe G, Heine A, Reuter K.

Biochemistry. 2018 Jul 3;57(26):3953-3965. doi: 10.1021/acs.biochem.8b00294. Epub 2018 Jun 14.

PMID:
29862811
18.

Washington state satellite HIV clinic program: a model for delivering highly effective decentralized care in under-resourced communities.

Wood BR, Bell C, Carr J, Aleshire R, Behrens CB, Dunaway SB, Shah JA, Barnabas RV, Green ML, Ramers CB, Fina PL, Kim HN, Harrington RD.

AIDS Care. 2018 Sep;30(9):1120-1127. doi: 10.1080/09540121.2018.1481194. Epub 2018 May 31.

19.

A novel protein-based prognostic signature improves risk stratification to guide clinical management in early-stage lung adenocarcinoma patients.

Martínez-Terroba E, Behrens C, de Miguel FJ, Agorreta J, Monsó E, Millares L, Sainz C, Mesa-Guzman M, Pérez-Gracia JL, Lozano MD, Zulueta JJ, Pio R, Wistuba II, Montuenga LM, Pajares MJ.

J Pathol. 2018 Aug;245(4):421-432. doi: 10.1002/path.5096. Epub 2018 Jun 20.

PMID:
29756233
20.

Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.

Kadara H, Choi M, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Yoo Y, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Wistuba II, Herbst RS.

Ann Oncol. 2018 Apr 1;29(4):1072. doi: 10.1093/annonc/mdx062. No abstract available.

PMID:
29688333
21.

Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy.

Pataer A, Shao R, Correa AM, Behrens C, Roth JA, Vaporciyan AA, Wistuba II, Swisher SG.

Cancer Med. 2018 Jun;7(6):2405-2414. doi: 10.1002/cam4.1505. Epub 2018 Apr 19.

22.

Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer.

Gomez DR, Byers LA, Nilsson M, Diao L, Wang J, Li L, Tong P, Hofstad M, Saigal B, Wistuba I, Kalhor N, Swisher S, Fan Y, Hong WK, Suraokar M, Behrens C, Moran C, Heymach JV.

Oncotarget. 2018 Jan 30;9(18):14268-14284. doi: 10.18632/oncotarget.24361. eCollection 2018 Mar 6.

23.

Detection of somatic mutations in cell-free DNA in plasma and correlation with overall survival in patients with solid tumors.

Mehrotra M, Singh RR, Loghavi S, Duose DY, Barkoh BA, Behrens C, Patel KP, Routbort MJ, Kopetz S, Broaddus RR, Medeiros LJ, Wistuba II, Luthra R.

Oncotarget. 2017 Oct 24;9(12):10259-10271. doi: 10.18632/oncotarget.21982. eCollection 2018 Feb 13.

24.

Immunohistochemical and Image Analysis-Based Study Shows That Several Immune Checkpoints are Co-expressed in Non-Small Cell Lung Carcinoma Tumors.

Parra ER, Villalobos P, Zhang J, Behrens C, Mino B, Swisher S, Sepesi B, Weissferdt A, Kalhor N, Heymach JV, Moran C, Zhang J, Lee J, Rodriguez-Canales J, Gibbons D, Wistuba II.

J Thorac Oncol. 2018 Jun;13(6):779-791. doi: 10.1016/j.jtho.2018.03.002. Epub 2018 Mar 8.

PMID:
29526824
25.

Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer.

Lee WC, Diao L, Wang J, Zhang J, Roarty EB, Varghese S, Chow CW, Fujimoto J, Behrens C, Cascone T, Peng W, Kalhor N, Moran CA, Weissferdt A, Johnson FM, William WN Jr, Swisher SG, Lee JJ, Hong WK, Heymach JV, Wistuba II, Futreal PA, Zhang J.

Mod Pathol. 2018 Jun;31(6):947-955. doi: 10.1038/s41379-018-0029-3. Epub 2018 Feb 6.

PMID:
29410488
26.

Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung Cancer.

Tang C, Hobbs B, Amer A, Li X, Behrens C, Canales JR, Cuentas EP, Villalobos P, Fried D, Chang JY, Hong DS, Welsh JW, Sepesi B, Court L, Wistuba II, Koay EJ.

Sci Rep. 2018 Jan 31;8(1):1922. doi: 10.1038/s41598-018-20471-5.

27.

The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network.

Tan X, Banerjee P, Liu X, Yu J, Gibbons DL, Wu P, Scott KL, Diao L, Zheng X, Wang J, Jalali A, Suraokar M, Fujimoto J, Behrens C, Liu X, Liu CG, Creighton CJ, Wistuba II, Kurie JM.

J Clin Invest. 2018 Apr 2;128(4):1267-1282. doi: 10.1172/JCI97225. Epub 2018 Feb 26.

28.

Cell-free one-pot conversion of (+)-valencene to (+)-nootkatone by a unique dye-decolorizing peroxidase combined with a laccase from Funalia trogii.

Kolwek J, Behrens C, Linke D, Krings U, Berger RG.

J Ind Microbiol Biotechnol. 2018 Feb;45(2):89-101. doi: 10.1007/s10295-017-1998-9. Epub 2017 Dec 22.

PMID:
29270883
29.

Development and Validation of a Predictive Radiomics Model for Clinical Outcomes in Stage I Non-small Cell Lung Cancer.

Yu W, Tang C, Hobbs BP, Li X, Koay EJ, Wistuba II, Sepesi B, Behrens C, Rodriguez Canales J, Parra Cuentas ER, Erasmus JJ, Court LE, Chang JY.

Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):1090-1097. doi: 10.1016/j.ijrobp.2017.10.046. Epub 2017 Nov 15.

PMID:
29246722
30.

Site-Specific 64Cu Labeling of the Serine Protease, Active Site Inhibited Factor Seven Azide (FVIIai-N3), Using Copper Free Click Chemistry.

Jeppesen TE, Kristensen LK, Nielsen CH, Petersen LC, Kristensen JB, Behrens C, Madsen J, Kjaer A.

Bioconjug Chem. 2018 Jan 17;29(1):117-125. doi: 10.1021/acs.bioconjchem.7b00649. Epub 2017 Dec 21.

PMID:
29206443
31.

Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer.

Sepesi B, Cuentas EP, Canales JR, Behrens C, Correa AM, Vaporciyan A, Weissferdt A, Kalhor N, Moran C, Swisher S, Wistuba I.

Semin Thorac Cardiovasc Surg. 2017 Autumn;29(3):408-415. doi: 10.1053/j.semtcvs.2017.05.008. Epub 2017 May 26.

PMID:
29195578
32.

Local Signals in Mouse Horizontal Cell Dendrites.

Chapot CA, Behrens C, Rogerson LE, Baden T, Pop S, Berens P, Euler T, Schubert T.

Curr Biol. 2017 Dec 4;27(23):3603-3615.e5. doi: 10.1016/j.cub.2017.10.050. Epub 2017 Nov 22.

33.

Ward round simulation in final year medical students: Does it promote students learning?

Behrens C, Dolmans DHJM, Leppink J, Gormley GJ, Driessen EW.

Med Teach. 2018 Feb;40(2):199-204. doi: 10.1080/0142159X.2017.1397616. Epub 2017 Nov 9.

PMID:
29117748
34.

Performance of the cobas HPV Test for the Triage of Atypical Squamous Cells of Undetermined Significance Cytology in Cervical Specimens Collected in SurePath.

Tewari D, Novak-Weekley S, Hong C, Aslam S, Behrens CM.

Am J Clin Pathol. 2017 Nov 2;148(5):450-457. doi: 10.1093/ajcp/aqx091.

PMID:
29045515
35.

Signatures of criticality arise from random subsampling in simple population models.

Nonnenmacher M, Behrens C, Berens P, Bethge M, Macke JH.

PLoS Comput Biol. 2017 Oct 3;13(10):e1005718. doi: 10.1371/journal.pcbi.1005718. eCollection 2017 Oct. Erratum in: PLoS Comput Biol. 2017 Dec 6;13(12 ):e1005886.

36.

Thy-1+ Cancer-associated Fibroblasts Adversely Impact Lung Cancer Prognosis.

Schliekelman MJ, Creighton CJ, Baird BN, Chen Y, Banerjee P, Bota-Rabassedas N, Ahn YH, Roybal JD, Chen F, Zhang Y, Mishra DK, Kim MP, Liu X, Mino B, Villalobos P, Rodriguez-Canales J, Behrens C, Wistuba II, Hanash SM, Kurie JM.

Sci Rep. 2017 Jul 25;7(1):6478. doi: 10.1038/s41598-017-06922-5.

37.

TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence.

Reuben A, Gittelman R, Gao J, Zhang J, Yusko EC, Wu CJ, Emerson R, Zhang J, Tipton C, Li J, Quek K, Gopalakrishnan V, Chen R, Vence LM, Cascone T, Vignali M, Fujimoto J, Rodriguez-Canales J, Parra ER, Little LD, Gumbs C, Forget MA, Federico L, Haymaker C, Behrens C, Benzeno S, Bernatchez C, Sepesi B, Gibbons DL, Wargo JA, William WN Jr, Swisher S, Heymach JV, Robins H, Lee JJ, Sharma P, Allison JP, Futreal PA, Wistuba II, Zhang J.

Cancer Discov. 2017 Oct;7(10):1088-1097. doi: 10.1158/2159-8290.CD-17-0256. Epub 2017 Jul 21.

38.

JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non-Small Cell Lung Cancer.

Shien K, Papadimitrakopoulou VA, Ruder D, Behrens C, Shen L, Kalhor N, Song J, Lee JJ, Wang J, Tang X, Herbst RS, Toyooka S, Girard L, Minna JD, Kurie JM, Wistuba II, Izzo JG.

Mol Cancer Ther. 2017 Oct;16(10):2234-2245. doi: 10.1158/1535-7163.MCT-17-0148. Epub 2017 Jul 20.

39.

Mechanistic differences in the uptake of salicylic acid glucose conjugates by vacuolar membrane-enriched vesicles isolated from Arabidopsis thaliana.

Vaca E, Behrens C, Theccanat T, Choe JY, Dean JV.

Physiol Plant. 2017 Nov;161(3):322-338. doi: 10.1111/ppl.12602. Epub 2017 Aug 4.

PMID:
28665551
40.

GLI1 Blockade Potentiates the Antitumor Activity of PI3K Antagonists in Lung Squamous Cell Carcinoma.

Kasiri S, Shao C, Chen B, Wilson AN, Yenerall P, Timmons BC, Girard L, Tian H, Behrens C, Wistuba II, Gazdar AF, Kim J.

Cancer Res. 2017 Aug 15;77(16):4448-4459. doi: 10.1158/0008-5472.CAN-16-3315. Epub 2017 Jun 26.

41.

Variants of PpuLcc, a multi-dye decolorizing laccase from Pleurotus pulmonarius expressed in Pichia pastoris.

Behrens CJ, Linke D, Allister AB, Zelena K, Berger RG.

Protein Expr Purif. 2017 Sep;137:34-42. doi: 10.1016/j.pep.2017.06.014. Epub 2017 Jun 23.

PMID:
28651974
42.

Chirp Mitigation of Plasma-Accelerated Beams by a Modulated Plasma Density.

Brinkmann R, Delbos N, Dornmair I, Kirchen M, Assmann R, Behrens C, Floettmann K, Grebenyuk J, Gross M, Jalas S, Mehrling T, Martinez de la Ossa A, Osterhoff J, Schmidt B, Wacker V, Maier AR.

Phys Rev Lett. 2017 May 26;118(21):214801. doi: 10.1103/PhysRevLett.118.214801. Epub 2017 May 23.

43.

Nonclinical pharmacokinetic and pharmacodynamic characterisation of somapacitan: A reversible non-covalent albumin-binding growth hormone.

Thygesen P, Andersen HS, Behrens C, Fels JJ, Nørskov-Lauritsen L, Rischel C, Johansen NL.

Growth Horm IGF Res. 2017 Aug;35:8-16. doi: 10.1016/j.ghir.2017.05.006. Epub 2017 May 24.

PMID:
28595133
44.

Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors.

Dalvi MP, Wang L, Zhong R, Kollipara RK, Park H, Bayo J, Yenerall P, Zhou Y, Timmons BC, Rodriguez-Canales J, Behrens C, Mino B, Villalobos P, Parra ER, Suraokar M, Pataer A, Swisher SG, Kalhor N, Bhanu NV, Garcia BA, Heymach JV, Coombes K, Xie Y, Girard L, Gazdar AF, Kittler R, Wistuba II, Minna JD, Martinez ED.

Cell Rep. 2017 May 23;19(8):1669-1684. doi: 10.1016/j.celrep.2017.04.077.

45.

Study of Preanalytic and Analytic Variables for Clinical Next-Generation Sequencing of Circulating Cell-Free Nucleic Acid.

Mehrotra M, Singh RR, Chen W, Huang RSP, Almohammedsalim AA, Barkoh BA, Simien CM, Hernandez M, Behrens C, Patel KP, Routbort MJ, Broaddus RR, Medeiros LJ, Wistuba II, Kopetz S, Luthra R.

J Mol Diagn. 2017 Jul;19(4):514-524. doi: 10.1016/j.jmoldx.2017.03.003. Epub 2017 May 12.

PMID:
28506684
46.

Towards ultrasound-guided adaptive radiotherapy for cervical cancer: Evaluation of Elekta's semiautomated uterine segmentation method on 3D ultrasound images.

Mason SA, O'Shea TP, White IM, Lalondrelle S, Downey K, Baker M, Behrens CF, Bamber JC, Harris EJ.

Med Phys. 2017 Jul;44(7):3630-3638. doi: 10.1002/mp.12325. Epub 2017 Jun 16.

47.

DNA methylation intratumor heterogeneity in localized lung adenocarcinomas.

Quek K, Li J, Estecio M, Zhang J, Fujimoto J, Roarty E, Little L, Chow CW, Song X, Behrens C, Chen T, William WN, Swisher S, Heymach J, Wistuba I, Zhang J, Futreal A, Zhang J.

Oncotarget. 2017 Mar 28;8(13):21994-22002. doi: 10.18632/oncotarget.15777.

48.

Role of CPS1 in Cell Growth, Metabolism and Prognosis in LKB1-Inactivated Lung Adenocarcinoma.

Çeliktas M, Tanaka I, Tripathi SC, Fahrmann JF, Aguilar-Bonavides C, Villalobos P, Delgado O, Dhillon D, Dennison JB, Ostrin EJ, Wang H, Behrens C, Do KA, Gazdar AF, Hanash SM, Taguchi A.

J Natl Cancer Inst. 2017 Mar 1;109(3):1-9. doi: 10.1093/jnci/djw231.

49.

Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer.

Kawakami M, Mustachio LM, Rodriguez-Canales J, Mino B, Roszik J, Tong P, Wang J, Lee JJ, Myung JH, Heymach JV, Johnson FM, Hong S, Zheng L, Hu S, Villalobos PA, Behrens C, Wistuba I, Freemantle S, Liu X, Dmitrovsky E.

J Natl Cancer Inst. 2017 Jun 1;109(6). doi: 10.1093/jnci/djw297.

50.

Connectomics of synaptic microcircuits: lessons from the outer retina.

Rogerson LE, Behrens C, Euler T, Berens P, Schubert T.

J Physiol. 2017 Aug 15;595(16):5517-5524. doi: 10.1113/JP273671. Epub 2017 May 4. Review.

Supplemental Content

Loading ...
Support Center